Considerations in retransplantation of the failed renal allograft recipient

被引:10
作者
Koch, MJ [1 ]
机构
[1] Washington Univ, Barnes Jewish Hosp, Sch Med, Dept Med,Div Nephrol, St Louis, MO 63110 USA
关键词
kidney; retransplantation; evaluation; allograft; outcomes;
D O I
10.1053/j.ackd.2005.10.004
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Routine success in kidney transplantation has significantly improved the quality and length of life for the majority of recipients and made this option the treatment of choice for suitable candidates. Improved patient survival combined with a relative static improvement in long-term graft outcomes has led to an increasing number of transplant recipients with failed allografts who face the eventual option of either returning to dialysis or seeking retransplantation. Although retransplantation is presumed to be a favorable option for many, data to support this belief is limited. Given the wide variance in predicted outcomes for retransplantation, on the basis of the underlying kidney disease and other individual patient comorbidities as well as the expected wait time for a second transplant, each case should be evaluated independently. This review discusses available data and individual considerations that should be taken into account when retransplantation is proposed after failure of a primary allograft. (c) 2006 by the National Kidney Foundation, Inc.
引用
收藏
页码:18 / 28
页数:11
相关论文
共 32 条
[1]
Intravenous immunoglobulin and Thymoglobulin facilitate kidney transplantation in complement-dependent cytotoxicity B-cell and flow cytometry T- or B-cell crossmatch-positive patients [J].
Akalin, E ;
Ames, S ;
Sehgal, V ;
Fotino, M ;
Daly, L ;
Murphy, B ;
Bromberg, JS .
TRANSPLANTATION, 2003, 76 (10) :1444-1447
[2]
Single-center long-term results of renal transplantation for IgA nephropathy [J].
Bumgardner, GL ;
Amend, WC ;
Ascher, NL ;
Vincenti, FG .
TRANSPLANTATION, 1998, 65 (08) :1053-1060
[3]
New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation [J].
Cosio, FG ;
Kudva, Y ;
van der Velde, M ;
Larson, TS ;
Textor, SC ;
Griffin, MD ;
Stegall, MD .
KIDNEY INTERNATIONAL, 2005, 67 (06) :2415-2421
[4]
Cruzado JM, 2002, NEW ENGL J MED, V347, P1531
[5]
Farney AC, 1996, CLIN TRANSPLANT, V10, P147
[6]
Clinical risk factors for recurrence of IgA nephropathy [J].
Freese, P ;
Svalander, C ;
Nordén, G ;
Nyberg, G .
CLINICAL TRANSPLANTATION, 1999, 13 (04) :313-317
[7]
Frohnert PP, 1997, CLIN TRANSPLANT, V11, P127
[8]
Retransplantation after kidney graft loss due to polyoma BK virus nephropathy: Successful outcome without original allograft nephrectomy [J].
Ginevri, F ;
Pastorino, N ;
de Santis, R ;
Fontana, I ;
Sementa, A ;
Losurdo, G ;
Santopietro, A ;
Perfumo, F ;
Locatelli, F ;
Maccario, R ;
Azzi, A ;
Comoli, P .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 42 (04) :821-825
[9]
ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. [J].
Gloor, JM ;
Lager, DJ ;
Moore, SB ;
Pineda, AA ;
Fidler, ME ;
Larson, TS ;
Grande, JP ;
Schwab, TR ;
Griffin, MD ;
Prieto, M ;
Nyberg, SL ;
Velosa, JA ;
Textor, SC ;
Platt, JL ;
Stegall, MD .
TRANSPLANTATION, 2003, 75 (07) :971-977
[10]
Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients [J].
Jordan, SC ;
Vo, A ;
Bunnapradist, S ;
Toyoda, M ;
Peng, A ;
Puliyanda, D ;
Kamil, E ;
Tyan, D .
TRANSPLANTATION, 2003, 76 (04) :631-636